Welcome : Guest
  • Only Report Titles
  • Titles & Keywords

TUBERCULOSIS THERAPEUTICS - A GLOBAL MARKET REPORT   

Research Abstract

This report analyzes the Global market for Tuberculosis Therapeutics in US$ Million. Annual estimates and forecasts are provided for the period 2006 through 2015. The report profiles 37 companies including AstraZeneca, Bayer AG, Bristol-Myers Squibb Co., Eli Lilly and Company, GlaxoSmithKline Plc, Lupin Limited, Novartis AG, Ranbaxy Laboratories Limited, Rusan Pharma Ltd., Rx for Africa, Inc., Sanofi-Aventis SA, Summit Plc, Tibotec BVBA, Otsuka Pharmaceutical Co., Ltd., AND Sequella, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Code : MCP-6337
Price : $3450
Companies : 37
Pages : 366
Date : April 2010
Market Data Tables : 90

Complimentary Market Brief:


Request a Complimentary Copy of the Report Insights, Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS

  TUBERCULOSIS THERAPEUTICS (Complete Report) Pages : 366   | $3450
 
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS3$100
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2  
   Data Interpretation & Reporting Level.....I-3
Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
II. EXECUTIVE SUMMARY49$2500
  1. INDUSTRY OVERVIEW.....II-121 $2150  
   Tuberculosis: A Reality Check.....II-1
Evolutionary Battle Against the TB Bug Drives the Future of the Market.....II-1
TB Prevalence Statistics: A Current Review.....II-1
1$100
   Table 1: Worldwide Prevalence of TB Cases (in 000s) by Region for the Year (2007) (includes corresponding Graph/Chart).....II-2

Table 2: Worldwide Incidence of TB Cases (in 000s) by Region for the Year (2007) (includes corresponding Graph/Chart).....II-2

Table 3: Worldwide TB Mortality (2009): Breakdown of Number of TB Deaths (in '000s) by Region (includes corresponding Graph/Chart).....II-2
Effectiveness of Current TB Management Strategies.....II-2
1$300
   Table 4: Currently Established TB First-Line Drugs, & Fixed-Dose Combination Drugs.....II-31$300
   Table 5: Currently Established TB Second-Line Drugs.....II-4
Renewed Interest in TB Drugs Development.....II-4
A Peek into the Current Drug Development Pipeline.....II-4
1$300
   TB Drugs in Pipeline as of the Year 2008.....II-51$100
   The Importance of Public-Private Partnerships (PPP).....II-61$100
   The Promise of New Therapeutic Advancements.....II-7
Nano Drug Delivery Offers a Ray of Hope.....II-7
1$100
   What’s The Need of the Hour?.....II-8
Moving Research to Market .....II-8
1$100
   Challenges in Drug Development.....II-9
Antidotes.....II-9
Recalibration of Drug Arsenal Against Resistant & HIV Co-Infected TB Cases.....II-9
1$100
   TB Research in Dire Need of Funding.....II-10
Table 6: Global Tuberculosis R&D Investment for the years 2005 through 2008 (In US$ Million) (includes corresponding Graph/Chart).....II-10
1$300
   Table 7: Worldwide TB Drugs Market (2007): Percentage Share Breakdown of Funding by Donor (includes corresponding Graph/Chart).....II-11

Table 8: Worldwide TB R&D Funding (2008): Percentage Share Breakdown of Allocated Funds by Area of Research (includes corresponding Graph/Chart).....II-11
1$300
   Table 9: Global Tuberculosis R&D Investment: Breakdown of R&D Sponsors for the year 2008 (In US$ Million).....II-12

Table 10: Global Tuberculosis R&D Investment (2008): Percentage Share Breakdown of Funds by Donor Type (includes corresponding Graph/Chart).....II-12
1$300
   Bottleneck in Logistics Need to be Ironed Out.....II-13
Other Trends & Issues.....II-13
The State of Research Funding Amidst the Recession .....II-13
Growth in Drug Resistant TB Cases Drive Second-Line Therapeutic Drugs Market.....II-13
1$100
   HIV Infections: A Major Catalyst in Global Increase of TB.....II-14
Pharma Companies Called Upon to Focus on TB Drug Development.....II-14
High Prevalence in Developing Countries offer a Strong Commercial Opportunity.....II-14
1$100
   Table 11: Prevalence of TB in High Burden Countries (2007): Percentage Share Breakdown of Prevalent Cases by Country (includes corresponding Graph/Chart).....II-151$300
   Table 12: Burden of TB Worldwide (2007): Breakdown of Number of cases of TB Prevalence (‘000s) by Country (includes corresponding Graph/Chart).....II-161$300
   Table 13: Burden of TB in High Burden Countries (2007): Breakdown of Number of Deaths (‘000s) by Country (includes corresponding Graph/Chart).....II-171$300
   A Peek Into the Commitments Voiced by High Burden Countries.....II-18
MDR-TB on the Rise in Dragon Land.....II-18
What’s the Chinese Government Doing About It?.....II-18
1$100
   Indonesia: Pledges Support to TB Drug Research.....II-19
South Africa Publicizes Its Commitment.....II-19
1$100
   Other Statistical Findings.....II-20
Table 14: Tuberculosis Prevalence in Japan: Breakdown of Notified Patients by Age Group for the year 2006 through 2008 (includes corresponding Graph/Chart).....II-20

Table 15: Tuberculosis Prevalence in Japan: Breakdown of Notified Patients by Gender for the year 2006 through 2008 (includes corresponding Graph/Chart).....II-20
1$300
   Table 16: Tuberculosis Prevalence in Japan: Breakdown of Notified Patients by Prefecture/Designated City for the year 2008 (includes corresponding Graph/Chart).....II-21
1$300
  2. DISEASE & TREATMENT OVERVIEW.....II-2212 $900  
   Tuberculosis (TB): A Prevalent, Yet Neglected Disease.....II-22
Latent TB Infection.....II-22
Active TB Infection.....II-22
A Peek Into the Bacteria Causing the Disease .....II-22
1$100
   Types of Tuberculosis.....II-23
Pulmonary Tuberculosis.....II-23
Extra Pulmonary Tuberculosis.....II-23
1$100
   Diagnosis of TB.....II-24
Prevention of TB.....II-24
The Cure.....II-24
2$200
   The DOTS Program: A Review.....II-26
TB Drugs.....II-26
First line Drugs.....II-26
Isoniazid.....II-26
1$100
   Mode of Action & Dosage.....II-27
Side Effects.....II-27
Rifampin.....II-27
1$100
   Mode of Action.....II-28
Side Effects.....II-28
Pyrazinamide.....II-28
1$100
   Dosage.....II-29
Mode of Action.....II-29
Side Effects.....II-29
Ethambutol.....II-29
Mode of Action.....II-29
Side Effects.....II-29
Streptomycin.....II-29
1$100
   Second Line Drugs.....II-30
Aminoglycosides.....II-30
Mode of Action.....II-30
1$100
   Fluoroquinolones.....II-311$100
   Moxifloxacin (MXF).....II-321$100
   Cycloserine.....II-33
p-aminosalicylic acid (PAS or P).....II-33
1$100
  3. RECENT INDUSTRY ACTIVITY.....II-346 $400  
   Across America Financial Services Acquires Apro Bio Pharmaceutical.....II-34
Academia Sinica Inks MoU with Infectious Disease Research Institute.....II-34
TB Alliance Enters into Collaboration with Tibotec.....II-34
1$100
   Rx for Africa Inks Letter of Intent with Rusan Pharma.....II-35
Johnson & Johnson to Establish Drug Research Centre.....II-35
Anacor Inks Agreements with Two Non-profit Organizations.....II-35
1$100
   Lupin Obtains USFDA Approval.....II-36
Sequella Commence Phase IB Study for SQ109.....II-36
Regional Model TB Center Establishes New Center.....II-36
AstraZeneca to Commence Safety Studies for TB Drug Candidate.....II-36
1$100
   GADD and TIM Enters into Partnership.....II-37
NWHD to Establish New Tuberculosis Facility.....II-37
Cadila Pharmaceuticals Launches Risorine.....II-37
Merck and Eli Lilly Collaborate for TB Treatment.....II-37
1$100
   Sanofi-aventis Enters into Collaboration with TB Alliance.....II-38
Summit Corp Enters into Co development Agreement with Lilly PPP.....II-38
NITD Collaborates with TB Alliance to Discover New Anti-TB Drugs.....II-38
Ranbaxy Enters into Alliance with DBT for TB Drug Discovery and Research.....II-38
1$100
   Sanofi pasteur Inks License and Research Agreement with SSI.....II-39
1$100
  4. FOCUS ON SELECT GLOBAL PLAYERS.....II-409 $700  
   Profiles of generic drug companies & pharma majors, developing TB drugs in
  collaboration with not-for profit organizations & academic institutes.....II-40
AstraZeneca (UK).....II-40
Bayer AG (Germany).....II-40
Bristol-Myers Squibb Co. (USA).....II-40
1$100
   Eli Lilly and Company (USA).....II-41
GlaxoSmithKline Plc. (UK).....II-41
Lupin Limited (India).....II-41
1$100
   Novartis AG (Switzerland).....II-42
Ranbaxy Laboratories Limited (India).....II-42
1$100
   Rusan Pharma Ltd., (India).....II-43
Rx for Africa, Inc., (USA).....II-43
1$100
   Sanofi-Aventis SA (France).....II-44
Summit Plc (UK).....II-44
1$100
   Tibotec BVBA (Belgium).....II-45
Otsuka Pharmaceutical Co., Ltd. (Japan).....II-45
Sequella, Inc., (USA).....II-45
1$100
   Profiles of key non-profit organizations & academic institutes.....II-46
Global Alliance for TB Drug Development (USA).....II-46
Research Project Pipeline of the Global Alliance for TB Drug Development As of the
  Year 2009.....II-46
2$200
   Institute of Microbiology, Chinese Academy of Sciences (China).....II-48
1$100
  5. GLOBAL MARKET PERSPECTIVE.....II-49   
   Table 17: World Recent Past, Current & Future Market Analysis for Tuberculosis (TB) Therapeutics Analyzed with Annual Sales in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-491$300
III. COMPETITIVE LANDSCAPE 307$995
  
Total Companies Profiled: 37 (including Divisions/Subsidiaries - 41)

Region/Country                 Players


The United States                 13
Canada                             1
Japan                              2	
Europe                            16
     France                        1
     Germany                       3
     The United Kingdom            5
     Italy                         1
     Spain                         1
     Rest of Europe                5
Asia-Pacific (Excluding Japan)     8
Africa                             1
Click here to request a full table of contents and more details on this project.		  
 
 

© Global Industry Analysts, Inc., USA. All Rights Reserved.
Visa Master American Verisign